Micropos Medical: Velindre Cancer Center Enters Agreement for the Implementation of the Raypilot System
Micropos Medical has entered into an agreement with Velindre Cancer Center to implement the Raypilot System, enabling high-precision radiation therapy for prostate cancer.
As part of the collaboration, Dr. Nachi Palaniappan and his team will implement ASBRT, with the aim of establishing the workflow and ultimately integrating the method as part of the clinic's standardized care for prostate cancer.
"Within prostate cancer care, the focus is increasingly shifting toward quality of life after treatment. ASBRT demonstrates excellent clinical outcomes with fewer side effects, while enabling treatment in as little as three to five days," says Richard Forsberg, CEO of Micropos Medical.
Installation of the system and treatment of the first patient are planned for the first quarter of 2026.
Dr. Nachi Palaniappan, Lead Radiation Oncologist at Velindre Cancer Center, comments:
"We have previous experience with SBRT, and this collaboration allows us to take the next step toward even greater precision and enhanced patient quality of life. The Raypilot System enables real-time tracking of prostate motion, reduces radiation exposure to healthy tissue, and allows for increased tumor dosage. This results in improved treatment outcomes and fewer side effects. Additionally, the system eliminates the need for surgically implanted gold markers."
Advancing the Role of Modern Radiation Therapy
Micropos Medical continues to strengthen awareness of modern radiation therapy as an effective and patient-friendly treatment option for prostate cancer among both patients and healthcare providers.
"There is strong and growing evidence that modern radiation therapy delivers excellent clinical results with clear benefits for patients. Our collaboration with Velindre Cancer Center marks an important step, and we look forward to enabling broader patient access to ASBRT as a standard treatment," concludes Richard Forsberg.